Octreotide LAR

DRUG18 trials

Sponsors

US Department of Veterans Affairs, Novartis, Novartis Pharmaceuticals, Radboud University Medical Center, NYU Langone Health

Conditions

AcromegalyAnemiaAscitesAutosomal Dominant Polycystic Kidney DiseaseCarcinoid Tumor of the Small BowelCarcinomatosisCirrhosisEsophageal Neuroendocrine Carcinoma

Phase 2

Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients

CompletedNCT00166725

NovartisProstate Cancer

Start: 2004-02-29Target: 40Updated: 2009-11-19

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

CompletedNCT00332696

Novartis PharmaceuticalsCarcinomatosis, Intestinal Obstruction, Peritoneal Neoplasms

Start: 2005-09-30End: 2008-09-30Updated: 2011-09-23

Everolimus and LongActing Octreotide Trial in Polycystic Livers

CompletedNCT01157858

Radboud University Medical CenterPolycystic Liver Disease

Start: 2010-06-30End: 2012-07-31Updated: 2015-06-29

Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET

CompletedNCT01567488

Grupo Espanol de Tumores NeuroendocrinosGastrointestinal Neoplasms

Start: 2011-06-08End: 2017-06-07Updated: 2018-01-03

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

TerminatedNCT01886287

H. Lee Moffitt Cancer Center and Research InstituteNeuroendocrine Carcinoma

Start: 2013-12-31End: 2014-10-31Updated: 2015-01-12

Octreotide LAR as Maintenance Treatment for Patients With NEC

Peking UniversityEsophageal Neuroendocrine Carcinoma, Gastro-entero-pancreatic Carcinoma

Start: 2015-04-30End: 2019-06-30Target: 92Updated: 2015-04-07

Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber

Radboud University Medical CenterAnemia, Gastrointestinal Hemorrhage, Hereditary Hemorrhagic Telangiectasia

Start: 2016-10-31End: 2018-10-31Target: 15Updated: 2018-04-20

Tolvaptan-Octreotide LAR Combination in ADPKD

CompletedNCT03541447

Mario Negri Institute for Pharmacological ResearchAutosomal Dominant Polycystic Kidney Disease

Start: 2018-12-12End: 2021-12-23Updated: 2022-11-03

Phase 3

Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

CompletedNCT00128232

NovartisAcromegaly

Start: 2002-12-31Target: 100Updated: 2012-04-30

Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly

CompletedNCT00225979

Novartis PharmaceuticalsAcromegaly

Start: 2002-11-30End: 2005-03-31Updated: 2012-04-11

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

CompletedNCT01578239

Advanced Accelerator ApplicationsCarcinoid Tumor of the Small Bowel, Neuroendocrine Tumour

Start: 2012-09-06End: 2021-01-18Updated: 2022-04-04

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Active, not recruitingNCT05050942

Camurus ABGastro-enteropancreatic Neuroendocrine Tumor

Start: 2021-10-22End: 2028-07-31Updated: 2025-11-06

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Active, not recruitingNCT05459844

Sinotau Pharmaceutical GroupNeuroendocrine Tumors

Start: 2022-08-31End: 2028-12-31Updated: 2025-09-05

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

RecruitingNCT06784752

Novartis PharmaceuticalsGastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Somatostatin Receptor Positive (SSTR+)

Start: 2025-05-30End: 2034-01-05Target: 240Updated: 2026-03-06

Phase 4

Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis

CompletedNCT00108355

US Department of Veterans AffairsAscites, Cirrhosis

Start: 2003-12-31End: 2012-08-31Updated: 2014-03-06

Surgical Debulking of Pituitary Adenomas

CompletedNCT01371643

NYU Langone HealthPituitary Adenoma

Start: 2004-04-30End: 2011-12-31Updated: 2016-08-29

Unknown Phase

Acromegaly Combination Treatment Study

TerminatedNCT01538966

Cedars-Sinai Medical CenterAcromegaly

Start: 2012-03-29End: 2022-05-20Updated: 2023-01-04

Real-world Study on Adjuvant Octreotide Therapy in pNETs

CompletedNCT06080204

Changhai HospitalPancreatic Neuroendocrine Tumor G2

Start: 2008-03-31End: 2020-04-30Updated: 2023-10-18

Related Papers

Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE.

2026-02-25

Radiation exposure and protection advice after [<sup>177</sup>Lu]Lu-DOTA-TATE therapy in China.

2024-11-281 citations

Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.

2024-01-165 citations

Nearly double the patients and dramatic changes over 14 years of UK MRT: Internal Dosimetry Users Group survey results from 2007 to 2021

Nuclear Medicine Communications2023-10-304 citations

Effects of Octreotide–Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial

Clinical Journal of the American Society of Nephrology2023-01-2823 citations

Methodology of the SORENTO clinical trial: Assessing the efficacy and safety of high exposure octreotide subcutaneous depot in patients with GEP-NETs.

Journal of Clinical Oncology2022-06-011 citations

<sup>177</sup>Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

2021-11-15378 citations

Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.

Journal of Clinical Oncology2021-05-2069 citations

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

European Journal of Nuclear Medicine and Molecular Imaging2020-03-02112 citations

Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study

Annals of Oncology2018-10-016 citations

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.

2018-05-2317 citations

First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.

Journal of Clinical Oncology2018-05-2028 citations

Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.

Journal of Clinical Oncology2017-02-013 citations

Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors

New England Journal of Medicine2017-01-113002 citations

NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with <sup>177</sup>Lu-DOTATATE.

Journal of Clinical Oncology2016-05-206 citations

NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate.

Journal of Clinical Oncology2016-02-0162 citations

Potential role of mTOR phosphorylation status as a negative predictor to everolimus plus octreotide in NETs.

Journal of Clinical Oncology2014-01-201 citations

The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis.

2012-07-1621 citations

Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial.

2011-11-2110 citations